Revenue
No reported data
FibroBiologics, Inc. (FBLG)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $7.4M | $4.5M | $2.4M | $1.1M |
| Operating expenses | $16.6M | $13.7M | $8.9M | $4.5M |
| Operating income | −$16.6M | −$13.7M | −$8.9M | −$4.5M |
| Net income | −$18.6M | −$11.2M | −$16.5M | −$5.1M |
| Basic EPSper diluted share | -$0.42 | -$0.34 | -$0.68 | -$0.18 |
| Diluted EPSper diluted share | -$0.42 | -$0.34 | -$0.68 | -$0.18 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 4, 2026Form 4 | Khoja HamidChief Scientific Officer | BuyCommon Stock | 30.0K | $0.38 | $11.4K | 61.3K |
| Mar 4, 2026Form 4 | O'HEERON PETECHIEF EXECUTIVE OFFICER | BuyCommon Stock | 15.9K | $0.38 | $6.0K | 5.96M |
| Mar 3, 2026Form 4 | O'HEERON PETECHIEF EXECUTIVE OFFICER | BuyCommon Stock | 18.2K | $0.41 | $7.5K | 5.94M |
| Mar 2, 2026Form 4 | O'HEERON PETECHIEF EXECUTIVE OFFICER | BuyCommon Stock | 17.4K | $0.35 | $6.1K | 5.92M |
| Mar 2, 2026Form 4 | Davis JasonChief Financial Officer | BuyCommon Stock | 70.0K | $0.41 | $28.7K | 70.0K |